🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Nilotinib

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  2. Nilotinib (AMN107)

    Novartis Pharmaceuticals

    Gastrointestinal Stromal Tumor (GIST)

    phase 3 small molecule completed

    1 trial

  3. Nimotuzumab

    Praxis Precision Medicines

    Pancreatic Cancer, Advanced or Metastatic

    phase 3 small molecule completed

    1 trial

  4. Nimotuzumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Nintedanib

    Boehringer Ingelheim

    Lung Diseases, Interstitial

    phase 3 small molecule completed

    1 trial

  6. Nintedanib

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  7. Nipocalimab

    Janssen Cilag International NV

    Sjogrens Syndrome

    phase 3 small molecule active

    1 trial

  8. Niraparib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  9. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  10. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  11. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  12. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  13. Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  14. NiuBangZi pill or NiuBangZi pill placebo

    Universal Integrated

    Niu Bang Zi Pill

    phase 3 small molecule active

    1 trial

  15. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  16. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  17. Nivolumab

    Ono Pharmaceutical Co.,

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  18. Nivolumab

    Shanghai Reinovax Biologics Co.,LTD

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  19. Nivolumab

    Bristol-Myers Squibb

    Head and Neck Cancer

    phase 3 mab completed

    1 trial

  20. Nivolumab

    Bristol-Myers Squibb

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  21. Nivolumab

    Bristol-Myers Squibb

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  22. Nivolumab

    Bristol-Myers Squibb

    Brain Neoplasms

    phase 3 small molecule completed

    1 trial

  23. Nivolumab

    Bristol-Myers Squibb

    Bladder Cancer

    phase 3 mab completed

    1 trial

  24. Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources